Breyanzi
| Breyanzi | |
|---|---|
| Term | Breyanzi |
| Short definition | Breyanzi - (pronounced) (brey-AN-zee) A drug used to treat adults with certain types of large B-cell lymphoma that have relapsed (returned) or failed to improve after treatment with at least one systemic therapy. It is also being studied in the treatment of other types of cancer. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
Breyanzi - (pronounced) (brey-AN-zee) A drug used to treat adults with certain types of large B-cell lymphoma that have relapsed (returned) or failed to improve after treatment with at least one systemic therapy. It is also being studied in the treatment of other types of cancer. Breyanzi is made using a patient's T cells (a type of cell in the immune system). A gene for a special receptor called the chimeric antigen receptor (CAR) is added to the T cells in the laboratory. Large numbers of these modified T cells, known as CAR T cells, are cultivated in the laboratory and given to the patient by infusion. Breyanzi attaches to a protein called CD19, which is found on most B-cell lymphoma cells. This helps the body's immune system kill cancer cells. Breyanzi is a form of CAR T cell therapy. Also called lisocabtagene maraleucel
External links
- Medical encyclopedia article on Breyanzi
- Wikipedia's article - Breyanzi
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski